Astellas pulls Japanese filing for darexaban
This article was originally published in Scrip
Executive Summary
Astellas has withdrawn a Japanese approval filing for its oral direct Factor Xa inhibitor darexaban maleate (YM150), citing a request from regulators for additional clinical studies.